Skip to main content
. Author manuscript; available in PMC: 2023 May 10.
Published in final edited form as: Neuropharmacology. 2022 Jan 24;208:108976. doi: 10.1016/j.neuropharm.2022.108976

Fig. 8. Experiment 2: Effects of pramipexole treatment on synapsin phosphorylation in the NAc, DS, VTA, CC, CeA, and PAG of rats.

Fig. 8.

(A) There was a significant interaction between CFA treatment and pramipexole treatment on pSynapsin in the NAc (p < 0.05). Post hoc analysis revealed a significant increase in pSynapsin of saline-pramipexole animals compared to saline-vehicle animals (**p < 0.01), but no difference in pSynapsin between CFA-vehicle and CFA-pramipexole animals (p > 0.05). (B) Pramipexole treatment increased pSynapsin in the DS (***p < 0.001). (C) Pramipexole treatment increased pSynapsin in the VTA (*p < 0.05). (D) Pramipexole treatment increased pSynapsin in the CC (*p < 0.05). (E) Pramipexole treatment increased pSynapsin in the CeA (*p < 0.05). (F) Pramipexole treatment increased pSynapsin in the PAG (*p < 0.05). Bars represent means and symbols represent individual data points.